Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: This paper aimed to review how scientific knowledge about the human psychobiology of MDMA has developed over time. Methods: In this paper, the empirical findings from earlier and later studies will be reviewed. Results: When MDMA was a ‘novel psychoactive substance’, it was not seen as a drug of abuse, as it displayed loss of efficacy. However, recreational users display a unique pattern of increasing doses, deteriorating cost–benefit ratios, and voluntary cessation. MDMA increases body temperature and thermal stress, with cortisol levels increased by 800% in dance clubbers. It can be extremely euphoric, although negative moods are also intensified. MDMA causes apoptosis (programmed cell death) and has been investigated for cancer therapy because of its anti‐lymphoma properties. Recreational users show deficits in retrospective memory, prospective memory, higher cognition, problem solving, and social intelligence. Basic cognitive skills remain intact. Neuroimaging studies show reduced serotonin transporter levels across the cerebral cortex, which are associated with neurocognitive impairments. Deficits also occur in sleep architecture, sleep apnoea, complex vision, pain, neurohormones, and psychiatric status. Ecstasy/MDMA use during pregnancy leads to psychomotor impairments in the children. Conclusions: The damaging effects of Ecstasy/MDMA are far more widespread than was realized a few years ago, with new neuropsychobiological deficits still emerging. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 5×
“Nutt et al. (2007) attempted to compare the relative dangers of the main types of psychosocial drug, using a series of subjective rating scales.”
BackgroundMethodInfluentialThe Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 3×
“Mithoefer et al. (2011) assessed 12 PTSD clients in their MDMA therapy group and eight clients in a placebo therapy group.”
BackgroundMethodVollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448 · cited 1×
“In a laboratory study involving MDMA administration, Vollenweider et al. (1998) excluded individuals with a personal psychiatric history, as certain psychiatric traits might increase the liability for ‘prolonged and severe responses to stimulant and hallucinogenic drugs’.”
BackgroundSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413 · cited 5×
“Greer and Tolbert (1986) similarly warned against using MDMA in psychiatrically vulnerable individuals: ‘There is an indication that MDMA may predispose people to a recurrence of previous psychological disabilities’.”
BackgroundInfluentialGender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360 · cited 4×
“Positive and negative mood changes often develop in the same individual, with feelings of happiness and depression, and extraversion and introversion, during the same Ecstasy/MDMA experience (Liechti et al., 2001).”
BackgroundInfluentialBedi, G., Hyman, D., & de Wit, H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.003 · Cited by 247 · cited 5×
“Bedi et al. (2010) reported significant increases in feeling loving and friendly. It is less widely recognized that negative moods are also boosted by MDMA, yet this has been repeatedly found in laboratory and field studies. Liechti et al. (2001) reported significant increases in self-rated apprehensiveness, depressio…”
BackgroundInfluentialCamí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234 · cited 11×
“In 2001, the higher cognitive skills of abstinent Ecstasy/MDMA users had hardly been assessed (Parrott, 2001). Since then, many studies have been undertaken, and they have revealed deficits in a range of complex cognitive measures. In one of the earliest studies to employ an extensive neurocognitive test battery, McCa…”
BackgroundResultInfluentialSubjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Harris, D. S., Baggott, M., Mendelson, J. H., Mendelson, J. E., & Jones, R. T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1131-1 · Cited by 229
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Dumont, G. J. H., & Verkes, R. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063271 · Cited by 149
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“Interpretation of this literature is sometimes complicated by poly drug use and the unknown content and dosage of black market ‘Ecstasy.’”
BackgroundInfluentialChi, T., & Gold, J. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116715 · Cited by 95
Bahji, A., Forsyth, A., Groll, D., & Hawken, E. R. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109735 · Cited by 88
Schenk, S., & Highgate, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15348 · Cited by 48
“Some users reported (1) taking more MDMA than they meant to (Parrott, 2013; Soar et al., 2006), (2) cravings (Davis & Rosenberg, 2014; Hopper et al., 2006; Huxster et al., 2006), (3) continuing to use MDMA despite adverse consequences (Cottler et al.,. ,2001, 2009; Yen & Hsu, 2007), (4) tolerance…”
BackgroundKamboj, S. K., Kilford, E. J., Minchin, S., Moss, A., Lawn, W., Das, R. K., Falconer, C. J., Gilbert, P., Curran, H. V., & Freeman, T. P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115587143 · Cited by 43
Sensitization to the Prosocial Effects of 3,4-Methylenedioxymethamphetamine (MDMA)
Curry, D. W., Berro, L. F., Belkoff, A. R., Sulima, A., Rice, K. C., & Howell, L. L. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.017 · Cited by 13
Metadata
- Authors
- Parrott, A. C.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 28
- Issue
- 4
- Pages
- 289-307
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1514792206
- Cited by
- 184
- References
- 12
- FWCI
- 25.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.